Sylvain Vigneault is the Country Manager for Viatris Australia. Overseeing the strategic direction of the business, he is responsible for leading a team of almost 800 employees Australia wide and supporting them to supply patients with access to more than 1,000 medicines.
Throughout 2020-2021, Sylvain guided the business through the transition to Viatris, which was formed through the combination of Mylan and Upjohn, a legacy division of Pfizer at the height of the COVID-19 pandemic.
Prior to this appointment, Sylvain held the role of Country Manager for Australia and Head of Commercial for New Zealand at Mylan for almost six years, following Mylan’s acquisition of Abbott EPD in 2015. Sylvain came to Australia in 2012 and was appointed General Manager Australia & New Zealand for Abbott EPD, based in Sydney.
In 2010, Sylvain started in the role of Commercial Director, RICC (Russia, India, China & CIS), where he led the development of the long-term strategy for the Cardiovascular and Vaccine portfolio. Sylvain has also held positions as Solvay’s Senior Vice President Neuroscience within the Global Product Strategy Department in Hannover, Germany, and then subsequently in Basel Switzerland.
Sylvain’s career began in Canada, and he has held roles in Czech Republic, France, Germany, Switzerland and Singapore before coming to Australia. Sylvain has also held the role of Chair of the Generic and Biosimilar Medicines Association from March 2018 to October 2020.